BMRN logo

BioMarin Pharmaceutical (BMRN) Cash From Investing

Annual CFI

-$111.24 M
-$91.22 M-455.41%

31 December 2023

BMRN Cash From Investing Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly CFI

-$16.16 M
-$106.64 M-117.86%

30 September 2024

BMRN Quarterly CFI Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

TTM CFI

-$4.88 M
+$29.64 M+85.87%

30 September 2024

BMRN TTM CFI Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

BMRN Cash From Investing Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-+75.1%+95.6%
3 y3 years+69.6%+70.8%+98.7%
5 y5 years-258.6%+67.0%+84.3%

BMRN Cash From Investing High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3 years-455.4%+69.6%-117.9%+75.1%at high+98.7%
5 y5 years-455.4%+69.6%-115.1%+93.5%-105.0%+98.7%
alltimeall time-142.1%+90.6%-103.5%+97.8%-101.0%+99.6%

BioMarin Pharmaceutical Cash From Investing History

DateAnnualQuarterlyTTM
Sept 2024
-
-$16.16 M(-117.9%)
-$4.88 M(-85.9%)
June 2024
-
$90.48 M(-735.6%)
-$34.52 M(-63.8%)
Mar 2024
-
-$14.24 M(-78.1%)
-$95.47 M(-14.2%)
Dec 2023
-$111.24 M(+455.4%)
-$64.96 M(+41.8%)
-$111.24 M(+10.2%)
Sept 2023
-
-$45.80 M(-255.1%)
-$100.99 M(+28.5%)
June 2023
-
$29.53 M(-198.4%)
-$78.59 M(-43.0%)
Mar 2023
-
-$30.01 M(-45.1%)
-$137.82 M(+588.1%)
Dec 2022
-$20.03 M(-94.5%)
-$54.71 M(+133.8%)
-$20.03 M(-3.4%)
Sept 2022
-
-$23.40 M(-21.2%)
-$20.74 M(-82.3%)
June 2022
-
-$29.70 M(-133.8%)
-$117.19 M(-43.6%)
Mar 2022
-
$87.78 M(-258.4%)
-$207.74 M(-43.3%)
Dec 2021
-$366.31 M(+583.2%)
-$55.42 M(-53.8%)
-$366.31 M(+22.2%)
Sept 2021
-
-$119.85 M(-0.3%)
-$299.87 M(+309.0%)
June 2021
-
-$120.26 M(+69.9%)
-$73.32 M(-63.7%)
Mar 2021
-
-$70.79 M(-742.0%)
-$201.81 M(+276.4%)
Dec 2020
-$53.62 M(+72.8%)
$11.03 M(-89.7%)
-$53.62 M(-52.8%)
Sept 2020
-
$106.70 M(-142.9%)
-$113.54 M(-33.8%)
June 2020
-
-$248.75 M(-421.4%)
-$171.56 M(-277.1%)
Mar 2020
-
$77.40 M(-258.3%)
$96.86 M(-412.2%)
Dec 2019
-$31.03 M(-111.7%)
-$48.90 M(-200.4%)
-$31.03 M(-41.6%)
Sept 2019
-
$48.68 M(+147.5%)
-$53.09 M(-117.7%)
June 2019
-
$19.67 M(-139.0%)
$300.56 M(+5.2%)
Mar 2019
-
-$50.48 M(-28.9%)
$285.61 M(+8.0%)
Dec 2018
$264.35 M(-186.5%)
-$70.96 M(-117.6%)
$264.35 M(-44.3%)
Sept 2018
-
$402.33 M(+8420.2%)
$474.86 M(-232.8%)
June 2018
-
$4.72 M(-106.6%)
-$357.69 M(-11.1%)
Mar 2018
-
-$71.73 M(-151.4%)
-$402.24 M(+31.7%)
Dec 2017
-$305.46 M(-36.9%)
$139.55 M(-132.4%)
-$305.46 M(-59.5%)
Sept 2017
-
-$430.23 M(+980.4%)
-$754.65 M(+15.9%)
June 2017
-
-$39.82 M(-259.0%)
-$651.36 M(+21.5%)
Mar 2017
-
$25.05 M(-108.1%)
-$536.00 M(+10.7%)
Dec 2016
-$484.05 M(-59.0%)
-$309.65 M(-5.3%)
-$484.05 M(+410.3%)
Sept 2016
-
-$326.94 M(-532.8%)
-$94.85 M(-156.1%)
June 2016
-
$75.54 M(-1.9%)
$169.01 M(-148.1%)
Mar 2016
-
$77.00 M(-3.2%)
-$351.73 M(-70.2%)
Dec 2015
-$1.18 B(-700.8%)
$79.55 M(-226.1%)
-$1.18 B(+48.1%)
Sept 2015
-
-$63.08 M(-85.8%)
-$796.47 M(-13.5%)
June 2015
-
-$445.20 M(-40.7%)
-$920.86 M(+78.5%)
Mar 2015
-
-$750.87 M(-262.3%)
-$516.02 M(-362.8%)
Dec 2014
$196.33 M(-165.7%)
$462.68 M(-346.8%)
$196.33 M(-134.3%)
Sept 2014
-
-$187.48 M(+364.5%)
-$572.84 M(+49.9%)
June 2014
-
-$40.36 M(+4.8%)
-$382.05 M(+16.0%)
Mar 2014
-
-$38.52 M(-87.4%)
-$329.43 M(+10.2%)
Dec 2013
-$298.85 M(+52.8%)
-$306.49 M(-9351.0%)
-$298.85 M(+568.3%)
Sept 2013
-
$3.31 M(-73.0%)
-$44.72 M(-35.2%)
June 2013
-
$12.26 M(-254.4%)
-$68.98 M(-70.5%)
Mar 2013
-
-$7.94 M(-84.8%)
-$233.62 M(+19.4%)
Dec 2012
-$195.65 M(+118.5%)
-$52.35 M(+149.9%)
-$195.65 M(+9.8%)
Sept 2012
-
-$20.95 M(-86.3%)
-$178.21 M(-17.3%)
June 2012
-
-$152.38 M(-607.3%)
-$215.58 M(+245.0%)
Mar 2012
-
$30.04 M(-186.0%)
-$62.49 M(-30.2%)
Dec 2011
-$89.56 M
-$34.91 M(-40.1%)
-$89.56 M(+31.2%)
DateAnnualQuarterlyTTM
Sept 2011
-
-$58.32 M(-8360.8%)
-$68.26 M(+389.6%)
June 2011
-
$706.00 K(-76.2%)
-$13.94 M(-49.8%)
Mar 2011
-
$2.97 M(-121.8%)
-$27.77 M(-72.6%)
Dec 2010
-$101.34 M(+27.2%)
-$13.61 M(+239.8%)
-$101.34 M(-23.9%)
Sept 2010
-
-$4.00 M(-69.5%)
-$133.25 M(-22.3%)
June 2010
-
-$13.13 M(-81.4%)
-$171.47 M(+39.9%)
Mar 2010
-
-$70.60 M(+55.1%)
-$122.58 M(+53.9%)
Dec 2009
-$79.67 M(+317.6%)
-$45.52 M(+7.8%)
-$79.67 M(-9.5%)
Sept 2009
-
-$42.23 M(-218.1%)
-$88.03 M(+166.1%)
June 2009
-
$35.76 M(-229.2%)
-$33.09 M(-77.7%)
Mar 2009
-
-$27.69 M(-48.6%)
-$148.13 M(+676.5%)
Dec 2008
-$19.08 M(-87.4%)
-$53.88 M(-523.7%)
-$19.08 M(-44.1%)
Sept 2008
-
$12.72 M(-116.0%)
-$34.13 M(-176.2%)
June 2008
-
-$79.28 M(-178.2%)
$44.77 M(-156.5%)
Mar 2008
-
$101.36 M(-247.0%)
-$79.26 M(-47.5%)
Dec 2007
-$151.00 M(-21.6%)
-$68.94 M(-175.2%)
-$151.00 M(-12.7%)
Sept 2007
-
$91.63 M(-145.1%)
-$172.97 M(-50.5%)
June 2007
-
-$203.31 M(-786.3%)
-$349.24 M(+100.8%)
Mar 2007
-
$29.63 M(-132.6%)
-$173.90 M(-9.8%)
Dec 2006
-$192.69 M(-456.3%)
-$90.91 M(+7.4%)
-$192.69 M(+83.1%)
Sept 2006
-
-$84.65 M(+202.7%)
-$105.22 M(+498.5%)
June 2006
-
-$27.96 M(-358.2%)
-$17.58 M(-152.0%)
Mar 2006
-
$10.83 M(-414.9%)
$33.84 M(-37.4%)
Dec 2005
$54.07 M(-284.0%)
-$3.44 M(-215.1%)
$54.07 M(-15.2%)
Sept 2005
-
$2.99 M(-87.3%)
$63.76 M(-12.6%)
June 2005
-
$23.45 M(-24.5%)
$72.98 M(+389.7%)
Mar 2005
-
$31.07 M(+397.3%)
$14.90 M(-150.7%)
Dec 2004
-$29.38 M(-42.3%)
$6.25 M(-48.8%)
-$29.38 M(-58.0%)
Sept 2004
-
$12.21 M(-135.3%)
-$70.01 M(-25.3%)
June 2004
-
-$34.62 M(+161.9%)
-$93.66 M(+14.8%)
Mar 2004
-
-$13.22 M(-61.6%)
-$81.58 M(+60.1%)
Dec 2003
-$50.95 M(-171.9%)
-$34.38 M(+200.3%)
-$50.95 M(-399.2%)
Sept 2003
-
-$11.45 M(-49.2%)
$17.03 M(-63.2%)
June 2003
-
-$22.54 M(-229.4%)
$46.31 M(-37.5%)
Mar 2003
-
$17.42 M(-48.2%)
$74.13 M(+4.5%)
Dec 2002
$70.91 M(-161.1%)
$33.60 M(+88.5%)
$70.91 M(-274.0%)
Sept 2002
-
$17.83 M(+237.5%)
-$40.74 M(-38.4%)
June 2002
-
$5.28 M(-62.8%)
-$66.16 M(-41.5%)
Mar 2002
-
$14.20 M(-118.2%)
-$113.03 M(-2.7%)
Dec 2001
-$116.13 M(+6663.5%)
-$78.05 M(+928.6%)
-$116.13 M(+229.2%)
Sept 2001
-
-$7.59 M(-81.8%)
-$35.27 M(+42.3%)
June 2001
-
-$41.59 M(-474.8%)
-$24.78 M(+127.1%)
Mar 2001
-
$11.10 M(+295.3%)
-$10.91 M(+535.5%)
Dec 2000
-$1.72 M(-97.5%)
$2.81 M(-3.3%)
-$1.72 M(-83.8%)
Sept 2000
-
$2.90 M(-110.5%)
-$10.57 M(-83.0%)
June 2000
-
-$27.72 M(-236.6%)
-$62.28 M(+33.2%)
Mar 2000
-
$20.29 M(-435.4%)
-$46.76 M(-32.0%)
Dec 1999
-$68.75 M(+738.4%)
-$6.05 M(-87.6%)
-$68.75 M(+9.6%)
Sept 1999
-
-$48.80 M(+300.0%)
-$62.70 M(+351.1%)
June 1999
-
-$12.20 M(+617.2%)
-$13.90 M(+717.2%)
Mar 1999
-
-$1.70 M
-$1.70 M
Dec 1998
-$8.20 M
-
-

FAQ

  • What is BioMarin Pharmaceutical annual cash flow from investing activities?
  • What is the all time high annual CFI for BioMarin Pharmaceutical?
  • What is BioMarin Pharmaceutical quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for BioMarin Pharmaceutical?
  • What is BioMarin Pharmaceutical quarterly CFI year-on-year change?
  • What is BioMarin Pharmaceutical TTM cash flow from investing activities?
  • What is the all time high TTM CFI for BioMarin Pharmaceutical?
  • What is BioMarin Pharmaceutical TTM CFI year-on-year change?

What is BioMarin Pharmaceutical annual cash flow from investing activities?

The current annual CFI of BMRN is -$111.24 M

What is the all time high annual CFI for BioMarin Pharmaceutical?

BioMarin Pharmaceutical all-time high annual cash flow from investing activities is $264.35 M

What is BioMarin Pharmaceutical quarterly cash flow from investing activities?

The current quarterly CFI of BMRN is -$16.16 M

What is the all time high quarterly CFI for BioMarin Pharmaceutical?

BioMarin Pharmaceutical all-time high quarterly cash flow from investing activities is $462.68 M

What is BioMarin Pharmaceutical quarterly CFI year-on-year change?

Over the past year, BMRN quarterly cash flow from investing activities has changed by +$48.81 M (+75.13%)

What is BioMarin Pharmaceutical TTM cash flow from investing activities?

The current TTM CFI of BMRN is -$4.88 M

What is the all time high TTM CFI for BioMarin Pharmaceutical?

BioMarin Pharmaceutical all-time high TTM cash flow from investing activities is $474.86 M

What is BioMarin Pharmaceutical TTM CFI year-on-year change?

Over the past year, BMRN TTM cash flow from investing activities has changed by +$106.37 M (+95.62%)